

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No.	Application No.		
US Patent and Trademark Office				050623.26	09/748,412		
INFORMATION DISCLOSURE CITATION in an Application				Applicant			
(Use several sheets if necessary)				Filing Date		Group Art Unit	
				December 21, 2000		3738	
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1						
	A2						
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation
	B1						Yes No
	B2						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	C1	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (1989).					
	C2	Komatsu et al., <i>Neointimal Tissue Response at Sites of Coronary Stenting in Humans, Macroscopic, Histological, and Immunohistochemical Analyses</i> , Circulation, 98:224-233 (1998).					
	C3	Matsumaru et al., <i>Embolic Materials for Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).					
	C4	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6):2490-2498 (1985).					
	C5	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).					
	C6	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Am. Heart J. 136(6):1081-1087 (1998).					
	C7	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125:212307 (1996).					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							